SLCO4C1 and pachyonychia congenita: In summary, our evidence supports the idea that hypermethylation in at least three sites inhibit the expression of SLCO4C1, which means that SLCO4C1 promoter methylation may play an important role in PC progression and that SLCO4C1 could be used potentially as a therapeutic target.